Patents by Inventor Tania Carmenate Portilla
Tania Carmenate Portilla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190315826Abstract: The present invention relates to the field of Biotechnology, particularly to a method based on the introduction of a single mutation in the genes encoding the human IL-2 and the muteins derived thereof that results in increased secretion levels in different hosts without affecting their biological functions. In particular, these mutations are based on a non-conservative change in the amino acid located in position 35 in the primary sequence of human IL-2, preferably the substitutions are K35E, K35D and K35Q. Another object of the present invention are the expression systems used to obtain both the recombinant human IL-2 and the muteins derived thereof using the method described in this invention. The above-mentioned method is useful to improve the production efficiency of the recombinant human IL-2 and the muteins derived thereof both at laboratory and industrial scales.Type: ApplicationFiled: November 10, 2017Publication date: October 17, 2019Inventors: GERTRUDIS ROJAS DORANTES, KALET LEÓN MONZÓN, TANIA CARMENATE PORTILLA
-
Patent number: 9701730Abstract: The present invention relates to the field of Biotechnology and more particularly to the mutated polypeptides of TGF? molecule whose primary sequence has a high homology with the sequence of human TGF?. These muteins lose their ability to interact with ALK5 but maintain their ability to interact with other receptors that are part of the receptor complex (T?RII and T?RIII). They have the property of antagonizing the signaling of all natural variants of TGF? ligands, dependent of ALK5 recruitment in the receptor complex, and have significant immunomodulatory effects. The present invention relates to pharmaceutical compositions comprising as active principle the polypeptides or fusion proteins disclosed and their use thereof given their modulating effect on the immune system in diseases such as cancer, diseases accompanied by fibrosis and chronic infectious diseases.Type: GrantFiled: October 30, 2013Date of Patent: July 11, 2017Assignee: Centro De Inmunologia MolecularInventors: Ángel de Jesús Corria Osorio, Kalet León Monzón, Tania Carmenate Portilla, Amaury Pupo Meriño, Saumel Pérez Rodríguez
-
Patent number: 9206243Abstract: The present invention relates to polypeptides which share primary sequence with human IL-2, except for several amino acids that have been mutated. The mutations introduced substantially reduce the ability of these polypeptides to stimulate in vitro and in vivo regulatory T cells (T CD4+CD25+FoxP3+) and make them more effective in the therapy of murine transplantable tumors. Also includes therapeutic uses of these mutated variants, used alone or in combination with vaccines for the therapy of diseases such as cancer or infections where the activity of regulatory T cells (Tregs) is relevant. In another aspect the present invention relates to pharmaceutical compositions comprising as active principle the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their modulating effect of the immune system on diseases like cancer and chronic infectious diseases.Type: GrantFiled: November 10, 2011Date of Patent: December 8, 2015Assignee: CENTRO DE IMMUNOLOGIA MOLECULARInventors: Kalet León Monzón, Tania Carmenate Portilla, Saumel Pérez Rodriguez, Neris Michel Enamorado Escalona, Agustin Bienvenido Lage Dávila
-
Publication number: 20150284441Abstract: The present invention relates to the field of Biotechnology and more particularly to the mutated polypeptides of TGF? molecule whose primary sequence has a high homology with the sequence of human TGF?. These muteins lose their ability to interact with ALK5 but maintain their ability to interact with other receptors that are part of the receptor complex (T?RII and T?RIII). They have the property of antagonizing the signaling of all natural variants of TGF? ligands, dependent of ALK5 recruitment in the receptor complex, and have significant immunomodulatory effects. The present invention relates to pharmaceutical compositions comprising as active principle the polypeptides or fusion proteins disclosed and their use thereof given their modulating effect on the immune system in diseases such as cancer, diseases accompanied by fibrosis and chronic infectious diseases.Type: ApplicationFiled: October 30, 2013Publication date: October 8, 2015Applicant: CENTRO DE INMUNOLOGIA MOLECULARInventors: Ángel de Jesús Corria Osorio, Kalet León Monzón, Tania Carmenate Portilla, Amaury Pupo Meriño, Saumel Pérez Rodríguez
-
Publication number: 20140314709Abstract: The present invention relates to polypeptides which share primary sequence with human IL-2, except for several amino acids that have been mutated. The mutations introduced substantially reduce the ability of these polypeptides to stimulate in vitro and in vivo regulatory T cells (T CD4+CD25+FoxP3+) and make them more effective in the therapy of murine transplantable tumors. Also includes therapeutic uses of these mutated variants, used alone or in combination with vaccines for the therapy of diseases such as cancer or infections where the activity of regulatory T cells (Tregs) is relevant. In another aspect the present invention relates to pharmaceutical compositions comprising as active principle the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptidess and pharmaceutical compositions disclosed due to their modulating effect of the immune system on diseases like cancer and chronic infectious diseases.Type: ApplicationFiled: November 10, 2011Publication date: October 23, 2014Applicant: CENTRO DE INMUNOLOGIA MOLECULARInventors: Kalet León Monzón, Tania Carmenate Portilla, Saumel Pérez Rodríguez, Neris Michel Enamorado Escalona, Agustín Bienvenido Lage Dávila
-
Patent number: 8759486Abstract: The present invention relates generally to polypeptides whose primary sequence has high sequence homology with human interleukin 2 (IL-2) with some punctual mutations in the sequence of native IL-2. The polypeptides of the present invention have an immunomodulatory effect on the immune system, which is selective/preferential on regulatory T cells. The present invention also relates to specific polypeptides whose amino acid sequence is disclosed herein. In another aspect the present invention relates to pharmaceutical compositions comprising as active ingredient the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their immune modulating effect on diseases such as cancer and chronic infectious diseases.Type: GrantFiled: November 26, 2010Date of Patent: June 24, 2014Assignee: Centro de Inmunologia MolecularInventors: Kalet León Monzón, Tania Carmenate Portilla, Karina García Martínez, Augustín Bienvendo Lage Davila, Samuel Pérez Rodríguez, Diamile González Roche, Gabriel Márquez Perera
-
Publication number: 20120315245Abstract: The present invention relates generally to polypeptides whose primary sequence has high sequence homology with human interleukin 2 (IL-2) with some punctual mutations in the sequence of native IL-2. The polypeptides of the present invention have an immunomodulatory effect on the immune system, which is selective/preferential on regulatory T cells. The present invention also relates to specific polypeptides whose amino acid sequence is disclosed herein. In another aspect the present invention relates to pharmaceutical compositions comprising as active ingredient the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their immune modulating effect on diseases such as cancer and chronic infectious diseases.Type: ApplicationFiled: November 26, 2010Publication date: December 13, 2012Applicant: CENTRO DE INMUNOLOGIA MOLECULAR (CIM)Inventors: Kalet León Monzón, Tania Carmenate Portilla, Karina García Martínez, Agustin Bienvendo Lage Davila, Samuel Pérez Rodríguez, Diamile González Roche, Gabriel Márquez Perera
-
Patent number: 6355414Abstract: The present invention is related to the field of medicine, particularly to the use of new adjuvant formulations with vaccine antigens. The technical objective pursued with this invention is, precisely, the development of formulations that are able to increase and/or modulate the immune response of the organism to vaccine antigens in the serum and the mucous lining. With this aim, a formulation was developed that contained as the main components the surface antigen of the hepatitis B virus and the acemannan in adequate proportions. As an extension of this result, formulations were developed in which a) HBsAg was used as the homologous or heterologous antigen carrier b) delivery systems of particulated antigens and c) soluble antigens, combined with the acemannan in specific proportions. The formulations of this invention are applicable in the pharmaceutical industry as vaccine formulations for human and veterinary use.Type: GrantFiled: January 6, 2000Date of Patent: March 12, 2002Assignee: Centro de Ingenieria Genetica y BiotechnologiaInventors: Julio Cesar Aguilar Rubido, Verena Lucila Muzio Gonzalez, Maria de Jesus Leal Angulo, Gerardo Enrique Guillen Nieto, Eduardo Penton Arias, Gloria Veliz Rios, Dagmara Pichardo Diaz, Antonieta Herrera Buch, Enrique Iglesias Perez, Luis Javier Cruz Ricondo, Tania Carmenate Portilla, Cirse Mesa Pardillo, Maydel Hechavarria Gay, Maylin Diaz Martinez, Juan Joel Madrazo Piñol